GlassScriptPhysician profile
Aurel Sara Apple
NPI 1558940296
$3,777.69
in general payments reported to CMS, 2019-2025
16 companies · $3,748 in 2025
The $3,748 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $29.70 · 2025: $3,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,679 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,678.69 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,104.86 | 2025 | |
| Galderma Laboratories, L.P. | $572.98 | 2025 | Nemluvio |
| Incyte Corporation | $399.73 | 2025 | Opzelura, Opzelura |
| Amgen INC. | $329.66 | 2024-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $241.04 | 2025 | Tremfya |
| Ucb, INC. | $197.32 | 2025 | Bimzelx |
| Genzyme Corporation | $185.10 | 2025 | |
| Leo Pharma INC. | $156.12 | 2025 | Anzupgo |
| Organon LLC | $124.52 | 2025 | Vtama |
| Blueprint Medicines Corporation | $122.61 | 2025 | |
| Novartis Pharmaceuticals Corporation | $115.65 | 2025 | |
| Sun Pharmaceutical Industries INC. | $58.53 | 2025 | |
| Pfizer INC. | $56.49 | 2025 | |
| Mayne Pharma Commercial LLC | $48.90 | 2025 | |
| Botanix Sb INC | $34.72 | 2025 | Sofdra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $29.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurel Apple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.